Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Blood (2012) 120 (10): 2098–2108.

https://doi.org/10.1182/blood-2012-01-407601

Published: 2012

Includes: Supplemental data

Journal Articles

DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia

Annegret Glasow, Angela Barrett, Kevin Petrie, Rajeev Gupta, Manuel Boix-Chornet, Da-Cheng Zhou, David Grimwade, Robert Gallagher, Marieke von Lindern, Samuel Waxman, Tariq Enver, Guido Hildebrandt, Arthur Zelent

Blood (2008) 111 (4): 2374–2377.

https://doi.org/10.1182/blood-2007-05-088344

Published: 2008

Includes: Supplemental data

Journal Articles

Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).

Qingping Cui, PhD, Haesook Kim, PhD, Da-Cheng Zhou, MD,PhD, Peter H. Wiernik, MD, Martin S. Tallman, MD, Robert E. Gallagher, MD

Blood (2007) 110 (11): 3167.

https://doi.org/10.1182/blood.V110.11.3167.3167

Published: 2007

Journal Articles

Increased Global Gene Promoter Methylation after Relapse (Rel) of Acute Promyelocytic Leukemia (APL) from All- trans Retinoic Acid (ATRA)-Containing Treatment Is Dissociated from Concurrent Gene Expression Changes.

Da-Cheng Zhou, MD, PhD, Qingping Cui, PhD, Haesook Kim, PhD, Reid Thompson, BS, John Greally, MD, PhD, Eric E. Bouhassira, PhD, Robert E. Gallagher, MD

Blood (2007) 110 (11): 2121.

https://doi.org/10.1182/blood.V110.11.2121.2121

Published: 2007

Journal Articles

Lack of Increased Gene Promoter Methylation at Relapse in Acute Promyelocytic Leukemia (APL).

Da-Cheng Zhou, MD,PhD, Reid Thompson, BS, Haesook Kim, PhD, John Greally, MD,PhD, Robert Gallagher, MD

Blood (2006) 108 (11): 4315.

https://doi.org/10.1182/blood.V108.11.4315.4315

Published: 2006

Journal Articles

DNA Methylation Independent Silencing of the RAR α Gene Expression in Acute Myeloid Leukemia.

Annegret Glasow, PhD, Angela Barrett, PhD, Manuel Boix Chornet, PhD, Rajeev Gupta, MD, Da-cheng Zhou, PhD, Robert Gallagher, MD, Marieke von Lindern, PhD, Samuel Waxman, MD, Tariq Enver, PhD, Guido Hildebrandt, MD, Arthur Zelent, PhD

Blood (2006) 108 (11): 2225.

https://doi.org/10.1182/blood.V108.11.2225.2225

Published: 2006

Journal Articles

Relapse of Acute Promyelocytic Leukemia (APL) Is Associated with Increased Methylation of the Retinoic Acid Receptor-Beta2 (RARβ2) Gene Promoter.

Da-Cheng Zhou, MD, PhD, Haesook Kim, PhD, Martin S. Tallman4, MD, Robert E. Gallagher, MD

Blood (2004) 104 (11): 1124.

https://doi.org/10.1182/blood.V104.11.1124.1124

Published: 2004

Journal Articles

Pyrosequencing Analysis of the Methylation Status of the CpG Island in the Retinoic Acid Receptor-β 2 (RAR-β 2 ) Gene Promoter.

Da-Cheng Zhou, MD, PhD, David Reynolds, Robert E. Gallagher, MD

Blood (2004) 104 (11): 4297.

https://doi.org/10.1182/blood.V104.11.4297.4297

Published: 2004

Journal Articles

Mutation of Cellular Retinoic Acid-Binding Protein-II (Crabp-II) Does Not Account for Resistance to All- Trans Retinoic Acid (ATRA) in Relapse Acute Promyelocytic Leukemia (APL).

Binu-John Sankoorikal, BS, Da-Cheng Zhou, MD, PhD, Peter H. Wiernik, MD, Robert E. Gallagher, MD

Blood (2004) 104 (11): 2081.

https://doi.org/10.1182/blood.V104.11.2081.2081

Published: 2004

Journal Articles

Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all- trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo

Da-Cheng Zhou, Soon H. Kim, Wei Ding, Cynthia Schultz, Raymond P. Warrell, Jr, Robert E. Gallagher

Blood (2002) 99 (4): 1356–1363.

https://doi.org/10.1182/blood.V99.4.1356

Published: 2002

NARROW

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia

Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).

Increased Global Gene Promoter Methylation after Relapse (Rel) of Acute Promyelocytic Leukemia (APL) from All- trans Retinoic Acid (ATRA)-Containing Treatment Is Dissociated from Concurrent Gene Expression Changes.

Lack of Increased Gene Promoter Methylation at Relapse in Acute Promyelocytic Leukemia (APL).

DNA Methylation Independent Silencing of the RAR α Gene Expression in Acute Myeloid Leukemia.

Relapse of Acute Promyelocytic Leukemia (APL) Is Associated with Increased Methylation of the Retinoic Acid Receptor-Beta2 (RARβ2) Gene Promoter.

Pyrosequencing Analysis of the Methylation Status of the CpG Island in the Retinoic Acid Receptor-β 2 (RAR-β 2 ) Gene Promoter.

Mutation of Cellular Retinoic Acid-Binding Protein-II (Crabp-II) Does Not Account for Resistance to All- Trans Retinoic Acid (ATRA) in Relapse Acute Promyelocytic Leukemia (APL).

Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all- trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only